Feed Top Reports Pricing

⌘K

07:10:20·261d

SECFiling

SEC Form 10-Q filed by Boundless Bio Inc.

BOLD· Boundless Bio Inc.

Health Care

Full content unavailable. See the original source below.

Original source

Companies

BOLD
Boundless Bio Inc.
Health Care

Recent analyst ratings

Jun 2UpdateH.C. Wainwright$5.00
May 28UpdateLeerink Partners$3.00
Dec 13UpdateGuggenheim-

Related

PR6d
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
SEC10d
Boundless Bio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation
PR37d
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
SEC45d
SEC Form 10-K filed by Boundless Bio Inc.
SEC45d
Boundless Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
PR45d
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
PR50d
Boundless Bio to Participate in the Leerink Global Healthcare Conference
PR52d
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022